

A study of 177 lutetium dotatate in children with primary refractory or relapsed high-risk neuroblastoma

Submission date 20/12/2013	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 20/12/2013	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 12/03/2020	Condition category Cancer	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

<http://www.cancerresearchuk.org/cancer-help/trials/a-trial-looking-177-lutetium-dotatate-neuroblastoma-children-young-people-ludo?>

Contact information

Type(s)

Scientific

Contact name

Miss Jennifer Laidler

Contact details

Cancer Research UK Clinical Trials Unit
Institute for Cancer Studies
Edgbaston
Birmingham
United Kingdom
B15 2TT

-
ludo@trials.bham.ac.uk

Additional identifiers

Clinical Trials Information System (CTIS)

2012-000510-10

Protocol serial number

13254

Study information

Scientific Title

A Phase IIa trial of 177 Lu DOTATATE in children with primary refractory or relapsed high-risk neuroblastoma

Acronym

LuDo

Study objectives

High-risk neuroblastoma is a common childhood cancer. Initial standard chemotherapy treatment produces responses in about two thirds of patients, many of whom will later relapse. The others have primary refractory disease. Overall cure rates are low, and so effective new treatments are needed.

Many neuroblastoma cells express somatostatin receptors. Radiolabelled octreotide analogues can be used for nuclear medicine imaging and therapy of somatostatin receptor positive tumours. 68Ga DOTATATE and 177Lu DOTATATE have been shown to be effective octreotide analogues for imaging and treatment respectively of neuroendocrine cancers in adults.

The primary aims of this study are to evaluate the toxicity and the efficacy of 177Lu DOTATATE in children with relapsed or refractory high-risk neuroblastoma. Secondary, translational, aims are to investigate 68Ga DOTATATE PET/CT for imaging of neuroblastoma, in comparison with the standard of 123I-mIBG, to assess the relationship between the expression of somatostatin receptors measured by immunohistochemistry in archived neuroblastoma tissue from each patient with their imaging, and to correlate tumour radiation dosimetry with response.

This will be a Phase II clinical trial using a Simon Two Stage Minimax design. This requires 14 patients in Stage 1. If three or more responses are seen, another 10 patients will be recruited in Stage 2. If eight or more responses are seen in these 24 patients, then the treatment will be deemed worthy of further investigation in this patient group.

Ethics approval required

Old ethics approval format

Ethics approval(s)

London-Hampstead Ethics Board, First MREC approval date 10/10/2012, ref: 12/LO/1422

Study design

Non-randomised interventional treatment trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Topic: National Cancer Research Network; Subtopic: Paediatric Oncology; Disease: Brain and Nervous System

Interventions

177Lutetium DOTATATE: The investigational medicinal product (IMP) for the study. Patients will receive up to a maximum of 4 administrations 8 weeks apart.

68Ga DOTATATE PET/CT: Potential patients for this study will require a 68Ga DOTATATE PET/CT to assess eligibility. Uptake in the tumour at least as high as the uptake in the liver must be demonstrated for a patient to be eligible.

Amino acid solution infusion: An amino acid solution is infused over 4 hours concurrently with the radionuclide administration to reduce renal tubular uptake and minimise nephrotoxicity.

SPECT/CT dosimetry: In radionuclide therapy there is an uncertain relationship between the administered activity (in GBq) of the drug and the absorbed dose (in Gray).

Therefore following administration whole body and SPECT/CT dosimetry will be performed to accurately determine the dose received by the whole body, bone marrow, kidneys and the tumour.

Whole blood profile: Weekly bloods will be taken to perform assessment of haematological toxicity

Study Entry : Registration only

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Lutetium dotatate

Primary outcome(s)

Response rate; Timepoint(s): 1 month

Key secondary outcome(s)

1. Overall survival; Timepoint(s): Follow up for 5 years
2. Progression-free survival; Timepoint(s): Follow up for 5 years
3. Toxic effects

Completion date

01/04/2015

Eligibility

Key inclusion criteria

1. Histologically confirmed diagnosis of neuroblastoma
2. Relapsed or primary refractory high-risk neuroblastoma (International Neuroblastoma Staging System stage 4 or International Neuroblastoma Risk Group staging System M)
3. Age >18 months and <18 years of age at the time of enrolment into the study
4. Life expectancy of greater than 3 months
5. Performance Status:
 - 5.1. Karnofsky 50% or more (for patients >12 years of age)
 - 5.2. Lansky 50% or more (for patients <12 years of age)
 - 5.3. Adequate recovery from major surgery prior to receiving study treatment

- 5.4. Uptake in primary tumour or metastatic tumour deposits on 68Gallium DOTATATE PET/CT at least as high as the liver uptake and performed within a month prior to trial
- 5.5. IMIBG and FDG PET/CT within a month prior to trial entry
- 5.6. Two-week washout from any prior treatment
- 5.7. Patients must have recovery of hematological toxicity following previous therapy
6. Laboratory requirements within 7 days of commencement of therapy
 - 6.1. Absolute neutrophil count $> 1.0 \times 10^9/L$
 - 6.2. Absolute platelets $> 100 \times 10^9/L$
7. Biochemistry:
 - 7.1. Bilirubin within normal range
 - 7.2. ALT within $2.5 \times ULN$
 - 7.3. ALP within $5 \times ULN$
 - 7.4. Glomerular filtration rate $>50 \text{ mL/min/1.73m}^2$
8. Before patient registration, written informed consent
9. Parents or other appropriate adult to sign the local Comforters and Carers consent before patient registration
10. Agreed to a follow-up of 5 years.

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Child

Lower age limit

18 months

Upper age limit

18 years

Sex

All

Total final enrolment

21

Key exclusion criteria

1. Not fit enough to undergo proposed study treatment
2. Concurrent treatment with any antitumour agents
3. Prior treatment with other radiolabelled somatostatin analogues
4. Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient or legal guardian before registration in the trial

Date of first enrolment

19/03/2013

Date of final enrolment

01/04/2015

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

Cancer Research UK Clinical Trials Unit

Birmingham

United Kingdom

B15 2TT

Sponsor information

Organisation

University of Birmingham (UK)

ROR

<https://ror.org/03angcq70>

Funder(s)

Funder type

Charity

Funder Name

Cancer Research UK (UK) Grant Codes: C17807/A14091

Alternative Name(s)

CR_UK, Cancer Research UK - London, Cancer Research UK (CRUK), CRUK

Funding Body Type

Private sector organisation

Funding Body Subtype

Other non-profit organizations

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/09/2020	12/03/2020	Yes	No
Basic results			21/06/2019	No	No
HRA research summary			28/06/2023	No	No